

**EKF Diagnostics Holdings plc**  
("EKF" or the "Company")

**Result of AGM and Voting Results**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The voting results of the AGM were as follows:

Resolution	For		Against		Withheld
	Votes	%	Votes	%	Votes
1	299,140,487	99.99%	25,430	0.01%	12,000
2	299,164,209	100.00%	1,708	0.00%	12,000
3	296,684,235	99.17%	2,481,682	0.83%	12,000
4	277,821,196	92.87%	21,344,721	7.13%	12,000
5	299,127,062	99.99%	38,855	0.01%	12,000
6	298,964,519	99.95%	158,855	0.05%	54,543
7	283,417,147	94.75%	15,704,227	5.25%	56,543
8	239,170,516	93.84%	15,704,227	6.16%	44,303,174
9	242,369,025	99.97%	72,261	0.03%	56,736,631
10	290,020,135	96.94%	9,145,782	3.06%	12,000

**EKF Diagnostics Holdings plc**  
Julian Baines, Executive Chair / Marc Davies, CFO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
Tel: +44 (0)29 2071 0570

**Singer Capital Markets (Nominated Adviser & Broker)**  
Aubrey Powell / George Tzimas / Oliver Platts

Tel: +44 (0)20 7496 3000

**Walbrook PR Limited**  
Paul McManus / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)  
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

**About EKF Diagnostics Holdings plc** ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGNKOBQKBKDOPD